P137 (0165) TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF VERY LATE RELAPSES (VLRs) OCCURRING ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY ± RADIOTHERAPY (CT ± RT) IN HODGKIN LYMPHOMA (HL): A JOINT STUDY FROM THE UNIVERSITY OF ATHENS AND ISTITUTO NAZIONALE DEI TUMORI MILANO

P137 (0165) 霍奇金淋巴瘤 (HL) 患者接受化疗±放疗 (CT±RT) 初始治疗 ≥5 年后发生的极晚期复发 (VLR) 的治疗策略和预后因素:雅典大学和米兰国家肿瘤研究所的联合研究

阅读:1

Abstract

Numerous consumer products, such as cosmetics, contain nanoparticles (NPs) of titanium dioxide (TiO(2)) or zinc oxide (ZnO); however, this raises questions concerning the safety of such additives. Most of these products do not indicate whether the product includes NPs. In this study, we characterized metal oxide NPs according to size, shape, and composition as well as their aggregation/agglomeration characteristics. In order to comprehend quickly the characterization of metal oxide NPs, we employed single particle inductively coupled plasma (SP-ICPMS) to help quantify the size of metal oxide NPs; then, we use transmission electron microscopy (TEM) to corroborate the results. The crystal size and structure was measured by X-ray diffraction (XRD), there are two crystal phase of TiO(2) NPs in sunscreen powder showed in XRD. However, SP-ICPMS proved highly effective in determining the size of NPs, the results of which remarkably good agreement with the TEM measurements. Pre-treatment included a conventional copper grid (requiring sample dilution) to evaluate the size, shape and composition of primary particles or plastic embedding (without the need for sample dilution) to evaluate the aggregate/aggregation of native NOAAs. The proposed method is an effective and fast approach to the characterization of oxide NPs in cosmetic sunscreen powder. These findings outline an alternative approach to the analysis of NPs in powder-form matrix.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。